Want Income for Life? Here Are 3 Stocks to Buy Now and Never Sell. A strong yield and an impressive track record of dividend growth aren't enough. The underlying business needs to be enduring.
Insider Moves Are Sending Mixed Signals Across the Tech Sector Broadcom sees insider selling after volatile 2026 trading, while Netskope draws heavy insider buying post-earnings drop and Eli Lilly CEO David Ricks purchases Adobe shares.
PINK vs. IXJ: Which Health Care ETF Is the Better Buy for Investors? PINK has stronger one-year and three-year returns, while IXJ offers lower costs and a higher dividend yield.
Which Healthcare ETF Is the Better Buy: iShares' Global IXJ or First Trust's Biotech FBT? One fund owns the giants of global healthcare, while the other bets on 30 smaller biotech companies.
IXJ vs. RSPH: Which Healthcare ETF Is the Better Buy? IXJ offers a higher dividend yield and lower volatility with global exposure, while RSPH's equal-weight approach posted a stronger 1-year return.
Novo Nordisk's Dividend Story Is Changing -- Here's What Investors Are Missing Novo Nordisk is offering an attractive 3.5% yield backed by a business where volume is the new focus.
Novo Nordisk Sues Eli Lilly Over Alleged Deceptive Weight Loss Drug Advertising Novo Nordisk has filed a lawsuit against Eli Lilly, alleging false advertising and deceptive marketing for Zepbound and Mounjaro treatments.
Which Is the Better Healthcare ETF, First Trust's Biotech-Focused FBT or State Street's Broader XLV? FBT delivered 52.4% returns over one year but with deeper drawdowns, while XLV's diversified approach offers lower costs and steadier performance.
Eli Lilly (LLY): Buy, Sell, or Hold Post Q1 Earnings? Eli Lilly has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 6.5% to $1,149 p...
Branded Pharmaceuticals Stocks Q1 Results: Benchmarking Merck (NYSE:MRK) The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a...
Now That Eli Lilly Trades Above $1,000, Is a Stock Split Finally on the Table? Investors have flocked to Eli Lilly for exposure to the high-growth weight loss drug market.
For Global Pharma Exposure Is the VanEck Pharmaceutical ETF or iShares Healthcare Fund the Better Buy in 2026? PPH's concentrated 26-stock portfolio delivered 28% returns over one year, while its 2% dividend yield beats IXJ by 50 basis points.
Will the Invesco Pharma ETF or iShares Global Healthcare Fund Be the Better Health Care Fund in 2026? IXJ offers broader diversification with 110 holdings and a lower 0.40% expense ratio, while PJP's concentrated U.S. pharma strategy delivered a 44.90% one-year return.
PJP vs. IYH: Which Healthcare ETF Is the Better Buy? PJP delivered a higher return over the past year -- but IYH charges lower fees and pays a higher dividend yield.
IHE vs. BBH: Which Healthcare ETF Is the Better Buy Right Now? BBH offers concentrated exposure to biotech, while IHE provides higher income with lower volatility by focusing on established drugmakers.
IHE vs IXJ: Which Popular Healthcare ETF Is the Better Buy for Investors? IHE's top two holdings account for over 43% of its portfolio, while IXJ spreads risk across 110 international stocks. Which concentration strategy fits your risk tolerance?
IXJ vs. IBBQ: Global Healthcare vs. Biotech -- Which ETF Is the Better Buy? IBBQ's concentrated biotech play has delivered a higher one-year return, while IXJ'S diversified global healthcare fund has been much less volatile.
The Most Overlooked Reason Eli Lilly Stock Keeps Surging -- and It Has Nothing to Do With Weight Loss There's a good reason why investors are focused on Eli Lilly's GLP-1 business, but there's more going on at the company.
